RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or polypropylene | Low-binding options reduce peptide adsorption |
| Typical shipping condition | Dry ice or gel packs | Choice depends on required temperature range |
| Light protection | Amber vial or foil wrap | Reduces photodegradation of sensitive residues |
| Reconstitution solvent | Water, buffer, or organic co-solvent | Depends on peptide solubility and assay requirements |
| Temperature monitoring | Data logger or indicator | Documents excursions during transport and storage |
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
Light, oxygen, and pH influence peptide integrity through specific side-chain reactions. Methionine and cysteine residues are susceptible to oxidation, and tryptophan can degrade under strong light. Inert gas overlays and amber glass or opaque containers reduce these risks. pH affects charge, solubility, and the rate of deamidation or aggregation; a value that minimizes one pathway may increase another. The optimal pH and buffer for a given peptide are often determined experimentally, and open questions remain about predicting stability from sequence alone.
Peptides are short chains of amino acids linked by amide bonds, and their storage stability depends on sequence, length, and three-dimensional structure. Chemical degradation can occur through hydrolysis, oxidation, deamidation, and aggregation, while physical changes such as precipitation or surface adsorption reduce recovery. Storage conditions are chosen to slow these processes without altering the peptide itself. Because peptides vary widely, no single condition suits every sequence, so laboratories often establish stability empirically for each batch.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
In March 2018, Russian president Vladimir Putin told journalist Megyn Kelly in an interview: "My point of view is that the individuals that have said that a new Cold War has started are not analysts. They do propaganda." Michael Kofman, a senior research scientist at the CNA Corporation and a fellow at the Wilson Center's Kennan Institute said that the causes and character of the new conflict between Russia and the West over Ukraine and Georgia are different from the Cold War. He said the Cold War "was a battle for global dominance between two universalist ideologies" while this new conflict for Russia "is about its survival as a power in the international order, and also about holding on to the remnants of the Russian empire". Lyle Goldstein, a research professor at the US Naval War College said that the situations in Georgia and Ukraine "seemed to offer the requisite storyline for new Cold War" between Russia and the West. Also in March 2018, Harvard University professors Stephen Walt, and then Odd Arne Westad, criticised the application of the term to increasing tensions between Russia and the West as "misleading", "distract[ing]", and too simplistic to describe the more complicated contemporary international politics. In October 2018, Russian military analyst Pavel Felgenhauer told Deutsche Welle that "we have a new Cold War, so the treaties that ended the previous one are irrelevant because they correspond to a totally different world situation", referring to the Intermediate-Range Nuclear Forces (INF) Treaty and others.
He decides to reenlist in the army and tells Amber, breaking their engagement. At the end of Season 5, Ryan gets into a car crash while drunk driving. Amber and his mother visit him, and Amber realizes that Ryan never told his mother about their former engagement. Amber and Ryan sleep together before Amber departs. Ryan is now living in Wyoming with his mother since he has been medically discharged from the army. His house is very small and messy, and it can be assumed that he doesn't do much each day. Amber visits him one day to reveal that she is pregnant with their child. He is thrilled and promises that he will be there for their baby. Amber is tempted to stay in Wyoming and take care of Ryan, but she decides that it is not best for the baby. In the series finale's flash-forward scene, Ryan is seen coming into Amber and Amber's husband's house. Ryan is bringing their son, Zeek (named after Amber's grandfather), home, while he and Amber are on friendly terms.
Labiaplasty (also known as labioplasty, labia minora reduction, and labial reduction) is a plastic surgery procedure for creating or altering the labia minora (inner labia) and the labia majora (outer labia), the folds of skin of the human vulva. It is a type of vulvoplasty. There are two main categories of women seeking cosmetic genital surgery: those with conditions such as intersex, and those with no underlying condition who experience physical discomfort or wish to alter the appearance of their vulvas because they believe they do not fall within a normal range. The size, colour, and shape of labia vary significantly, and may change as a result of childbirth, aging, and other events. Conditions addressed by labiaplasty include congenital defects and abnormalities such as vaginal atresia (absent vaginal passage), Müllerian agenesis (malformed uterus and fallopian tubes), intersex conditions (male and female sexual characteristics in a person); and tearing and stretching of the labia minora caused by childbirth, accident, and age. In feminizing vaginoplasty for the creation of a neovagina, labiaplasty creates labia where once there were none. A 2008 study reported that 32 percent of women who underwent the procedure did so to correct a functional impairment; 31 percent to correct a functional impairment and for aesthetic reasons; and 37 percent for aesthetic reasons alone. According to a 2011 review, overall patient satisfaction is in the 90–95 percent range.
==== Uganda ==== The most common agricultural supply chain in Uganda involves farmers selling their produce to wholesalers, who in turn sell to retailers in fresh food markets. A 2006 study in the areas around Kampala and Mbale found that 51% of farmers sold to wholesalers and 18% sold directly to market vendors, while 34% of the wholesalers sold to market vendors. The customers of the markets in the study were predominantly end consumers, although a small share of the markets also sold to restaurants.
=== Insertion of transgenes === To integrate a gene fragment of interest into the Sendai virus genome, the following protocol might be used. The amplified gene fragment is inserted into a Sendai virus vector lacking the F protein (SeV/ΔF). The recovery and amplification of SeV/ΔF vectors proceed as follows: Transfection: 293T cells are transfected with the pSeV/ΔF template containing the transgene of interest, along with plasmids that encode the T7 RNA polymerase and the viral genes NP, P, F5R (a modified F protein), and L. Cultivation: Post-transfection, the cells are incubated and cultured for 1 to 3 days to produce the initial SeV/ΔF vector. Propagation: The vector is then propagated in LLC-MK2/F7/A cells, a specialized cell line of LLC-MK2 that expresses the Sendai virus F protein, in a medium that includes trypsin. Titer quantification: The titers of the harvested SeV vector are determined by measuring the cell infectious units (CIU) per milliliter through immunostaining with anti-SeV rabbit polyclonal serum.
Sources: en.wikipedia.org
== History == The sucrose hemolysis test was developed in the 1960s. Hartmann and Jenkins first described the test in 1966. The test was devised as a superior screen for PNH compared to the Ham's acid hemolysis test (HT) that was developed in the 1930s. For decades, these two tests were the primary methods of diagnosing PNH. The test is now obsolete being replaced by more advanced methods such as flow cytometry with monoclonal antibodies CD55/CD59 that target glycosylphosphatidylinositol-anchored proteins (GPI-AP) with the addition of inactivated fluorescently labeled bacterial toxins, such as fluorescently labeled aerolysin (FLAER). Flow cytometry is the most sensitive and useful assay currently available to screen and diagnosis PNH.
She works with several biopharmaceutical companies to apply new mass spectrometry techniques to new drug modalities including monoclonal antibodies. She also develops new mass spectrometry instrumentation. Her group looks at the structure of biological systems at a molecular level, studying them in the gas and solution phase as well as theoretically. They use electrospray ionization, mass spectrometry, ion mobility mass spectrometry native mass spectrometry and complementary solution based biophysical techniques. They are interested in a proteins structure and how it changes in an effort to relate that to their function. Ion-mobility spectrometry–mass spectrometry can be used to look at the temperature dependent rotationally averaged collision cross-section of gas-phase ions of proteins. In 2014 she was awarded a Biotechnology and Biological Sciences Research Council grant to study the interactions of proteins with other proteins. Barran serves on the editorial board of the International Journal of Mass Spectrometry. She was included in the page of Perditas created by Perdita Stevens.
== Flavouring properties == Glycyrrhizin is obtained as an extract from licorice root after maceration and boiling in water. Licorice extract (glycyrrhizin) is sold in the United States as a liquid, paste, or spray-dried powder. When in specified amounts, it is approved for use as a flavor and aroma in manufactured foods, beverages, candies, dietary supplements, and seasonings. It is 30 to 50 times as sweet as sucrose (table sugar).
=== Discovery and initial characterization === Radioactivity was discovered in 1896 by Henri Becquerel in uranium, and subsequently observed by Marie and Pierre Curie in thorium and in the newly discovered elements polonium and radium. In 1899, Ernest Rutherford separated radioactive emissions into two types: alpha and beta (now beta minus), based on penetration of objects and ability to cause ionization. Alpha rays could be stopped by thin sheets of paper or aluminium, whereas beta rays could penetrate several millimetres of aluminium. In 1900, Paul Villard identified a still more penetrating type of radiation, which Rutherford termed gamma rays. In 1900, Becquerel measured the mass-to-charge ratio (m/e) for beta particles by the method of J.J. Thomson used to study cathode rays and identify the electron. He found that m/e for a beta particle is the same as for Thomson's electron, and therefore suggested that the beta particle is in fact an electron. In 1901, Rutherford and Frederick Soddy showed that alpha and beta radioactivity involves the transmutation of atoms into atoms of other chemical elements. In 1913, after the products of more radioactive decays were known, Soddy and Kazimierz Fajans independently proposed their radioactive displacement law, which states that beta (i.e., β−) emission from one element produces another element one place to the right in the periodic table, while alpha emission produces an element two places to the left.
Subsequent research suggests that multiple waves of immune cells develop through hematopoiesis from hemogenic endothelial cells (ECs), independent of HSCs, with HSCs arising in a later hematopoietic wave. Tissue-resident immune cells may be either fetal-derived or the progeny of adult HSCs. In vertebrates, the earliest source of mast cells is the extraembryonic yolk sac, where blood and immune cells first develop. However, there are differences in the embryonic development of vertebrates such as mice compared to primates (including humans). In primates, yolk sac formation involves a transient primary yolk sac, and the formation of extraembryonic mesoderm, prior to generation of a secondary yolk sac where the first blood cells of the embryo develop. During embryonic development, mast cell progenitors (MCps) form in a series of developmentally discrete waves. The first wave of mast cells in the embryo is derived from erythro-myeloid progenitors (EMPs) in the yolk sac, before hematopoietic stem cells (HSC) emerge. In mouse models, the earliest mast cell progenitors originate in the embryo around embryonic day 7 (E7.5-E8.5). Transient erythro-myeloid progenitors (EMPs) develop in the yolk sac between E8.5-E10.5 and in fetal liver (FL) between E11.5-E13.5. Embryonic multipotent progenitors (eMPPs) and hematopoietic stem cells (HSCs) emerge around E10.5. Mast cell differentiation in the fetal liver (FL) starts from E11, along with a peak in the number of mast cell progenitors.
Sources: en.wikipedia.org
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.
Aliquots limit repeated thawing and refreezing and repeated vial opening, both of which can promote degradation. They also reduce the chance of contaminating an entire batch. Single-use portions should be labeled with identity, concentration, solvent, and date.
Inspect the package for damage and confirm that temperature indicators or data loggers stayed within the specified range. Check the vial condition and labeling before placing it into storage. Record any excursion or discrepancy for the supplier or quality system.
Freezing slows hydrolysis and oxidation by reducing molecular motion and available water. Lyophilized powders contain little moisture, so they can remain stable for extended periods when kept cold and dry. The exact temperature depends on peptide sequence and expected storage duration.